This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Claus Ehrhardt - Innovator in Pharmaceutical Research
Introduction
Claus Ehrhardt is a notable inventor based in Basel, Switzerland. He is currently associated with Novartis AG, a leading global healthcare company. Although he does not hold any granted patents, his contributions to pharmaceutical research are significant.
Latest Patent Applications
Claus Ehrhardt has been involved in several innovative projects, leading to the following latest patent applications:
1. **Compounds and Compositions as Sppl2a Inhibitors** - This invention relates to tricyclic compounds comprising a diazepinone moiety that are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a). It includes pharmaceutical compositions containing such inhibitors and methods of using these inhibitors and compositions.
2. **Kallikrein 7 Modulators** - This invention pertains to the crystal structure of the serine protease kallikrein 7 and its application in drug discovery. It also involves compounds that bind specifically to the active site of kallikrein 7.
Conclusion
Claus Ehrhardt's work at Novartis AG showcases his commitment to advancing pharmaceutical science through innovative research and development. His latest patent applications reflect his dedication to finding new therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile